Price movement over the last 24 hours
Alcon AG vs General Mills, Inc. — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while General Mills, Inc. trades at $36.6 (market cap $19.80B). The key difference: Alcon AG is the larger of the two by market cap, and General Mills, Inc. pays the higher dividend (6.58%). Which is the better fit depends on your goals.
| ALC | GIS | |
|---|---|---|
Market Cap | $32.69B | $19.80B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $51.84 |
52-Week Low | $62.02 | $32.17 |
Enterprise Value | $36.28B | $33.29B |
Dividend Yield | 0.54% | 6.58% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
General Mills (GIS) trades at $37.10, down 1.25% on the day, with a bullish technical signal from moving averages and a neutral RSI near 58. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. The company maintains a dividend of $0.61 per share and is implementing cost-saving initiatives targeting $3B by 2030 to counter margin pressures from private-label competition.
Outlook: GIS presents a value opportunity with a low P/E of 9.23, but faces headwinds from sluggish sales and negative net income margin. Risks include consumer spending shifts and high debt levels. Analyst consensus is cautious with a hold-heavy rating and a $36.14 price target slightly below current levels, suggesting limited near-term upside without stronger earnings growth.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →